HLS Therapeutics (TSE:HLS) Stock Price Down 1.3% – Here’s Why

HLS Therapeutics Inc. (TSE:HLS)’s share price fell 1.3% on Monday . The stock traded as low as C$4.35 and last traded at C$4.41. 3,010 shares were traded during trading, a decline of 62% from the average session volume of 8,021 shares. The stock had previously closed at C$4.47.

HLS Therapeutics Stock Performance

The company has a debt-to-equity ratio of 75.00, a quick ratio of 1.01 and a current ratio of 1.00. The firm’s 50-day moving average price is C$4.55 and its two-hundred day moving average price is C$4.62. The firm has a market capitalization of C$137.92 million, a price-to-earnings ratio of -13.78 and a beta of -0.02.

HLS Therapeutics (TSE:HLS) last issued its earnings results on Friday, May 15th. The company reported C($0.10) earnings per share for the quarter. HLS Therapeutics had a negative net margin of 18.42% and a negative return on equity of 16.54%. The business had revenue of C$17.88 million for the quarter. Sell-side analysts predict that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.